title: Sarpogrelate, a specific 5HT2-receptor antagonist, improves the coronary microcirculation in coronary artery disease.
abstract: BACKGROUND
  Serotonin (5-hydroxytryptamine: 5-HT) reduces the coronary blood flow (CBF) as a product of aggregating platelets. Sarpogrelate, a specific 5HT2-receptor antagonist, has been reported to increase the coronary collateral flow in humans: however, its effect on the microcirculation is still not fully understood.
  
  
  OBJECTIVE
  This study was undertaken to determine whether sarpogrelate might improve the microcirculation in coronary artery disease (CAD).
  
  
  METHODS
  To investigate the effect of sarpogrelate on the microcirculation in CAD, we measured CBF in 15 patients with CAD but no significant stenosis in the left anterior descending artery (LAD). The patients were randomly allocated to two groups, including those receiving oral administration of 200 mg of sarpogrelate (SPG, 8 patients, age 61 +/- 6 years) and those receiving no medication (controls, 7 patients, age 57 +/- 8 years). Prior to and 1 h after the administration of sarpogrelate, or in controls at 1-h intervals, the average peak velocity (APV) at baseline and hyperemia was measured by an intracoronary Doppler guidewire. Systemic blood pressure (SBP) and cardiac output (CO) were also measured.
  
  
  RESULTS
  In the patients receiving SPG, the medication significantly increased the baseline (18 +/- 9 to 19 +/- 10 cm/s, p < 0.05) and maximal APV (55 +/- 9 to 64 +/- 31 cm/s, p<0.05). However, no significant changes were observed in SBP and CO after the administration of SPG. In the control group, there were no significant differences in baseline and hyperemic APV.
  
  
  CONCLUSIONS
  Sarpogrelate increased both baseline and maximal CBF without changing the systemic hemodynamics. These findings thus support that SPG improves the microcirculation by antagonizing the vasoconstrictive products of the aggregating platelets in CAD.
authors.affiliation: National Defense Medical College, Internal Medicine-1, Saitama, Japan.
authors.forename: Kimio
authors.initials: K
authors.lastname: Satomura
authors.forename: Bonpei
authors.initials: B
authors.lastname: Takase
authors.forename: Akira
authors.initials: A
authors.lastname: Hamabe
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Ashida
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Hosaka
authors.forename: Fumitaka
authors.initials: F
authors.lastname: Ohsuzu
authors.forename: Akira
authors.initials: A
authors.lastname: Kurita
mesh_terms: D000368:Aged; D003326:Coronary Circulation / Q000187:drug effects*; D003327:Coronary Disease / Q000188:drug therapy* / Q000503:physiopathology; D003331:Coronary Vessels / Q000187:drug effects; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D015150:Echocardiography, Doppler; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D011985:Receptors, Serotonin / Q000187:drug effects*; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D013386:Succinates / Q000008:administration & dosage / Q000494:pharmacology*; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D013386:Succinates; C064294:sarpogrelate